Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Silence Therapeutics (SLN) EBIT Margin: 2020-2025

Historic EBIT Margin for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -16,505.66%.

  • Silence Therapeutics' EBIT Margin fell 1450319.00% to -16,505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -321.21%, marking a year-over-year increase of 4512.00%. This contributed to the annual value of -146.38% for FY2024, which is 5709.00% up from last year.
  • As of Q3 2025, Silence Therapeutics' EBIT Margin stood at -16,505.66%, which was down 54.29% from -10,697.77% recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' EBIT Margin ranged from a high of -17.20% in Q4 2024 and a low of -20,006.34% during Q1 2025.
  • In the last 3 years, Silence Therapeutics' EBIT Margin had a median value of -633.59% in 2023 and averaged -4,868.51%.
  • In the last 5 years, Silence Therapeutics' EBIT Margin soared by 61,639bps in 2024 and then slumped by 1,997,079bps in 2025.
  • Silence Therapeutics' EBIT Margin (Quarterly) stood at -329.91% in 2021, then soared by 9,987bps to -230.03% in 2022, then slumped by 40,356bps to -633.59% in 2023, then soared by 61,639bps to -17.20% in 2024, then plummeted by 1,450,319bps to -16,505.66% in 2025.
  • Its EBIT Margin stands at -16,505.66% for Q3 2025, versus -10,697.77% for Q2 2025 and -20,006.34% for Q1 2025.